Literature DB >> 27733072

Not just leukemia: CMV may protect against lymphoma recurrence after allogeneic transplant.

Jonathan U Peled1, Robert R Jenq1.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27733072      PMCID： PMC5354121          DOI： 10.1080/10428194.2016.1239265

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  35 in total

1.  CMV-specific cellular therapy for acute myeloid leukemia?

Authors:  Kirsty J Thomson; Stephen Mackinnon; Karl S Peggs
Journal:  Blood       Date:  2012-01-26       Impact factor: 22.113

2.  Improvement of adult T-cell lymphoma/leukaemia by antiviral drugs including foscarnet.

Authors:  Y Takimoto
Journal:  Br J Haematol       Date:  1998-08       Impact factor: 6.998

3.  CMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCRβ repertoire.

Authors:  Yvonne Suessmuth; Rithun Mukherjee; Benjamin Watkins; Divya T Koura; Knut Finstermeier; Cindy Desmarais; Linda Stempora; John T Horan; Amelia Langston; Muna Qayed; Hanna J Khoury; Audrey Grizzle; Jennifer A Cheeseman; Jason A Conger; Jennifer Robertson; Aneesah Garrett; Allan D Kirk; Edmund K Waller; Bruce R Blazar; Aneesh K Mehta; Harlan S Robins; Leslie S Kean
Journal:  Blood       Date:  2015-04-07       Impact factor: 22.113

4.  Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients.

Authors:  Ahmet H Elmaagacli; Nina K Steckel; Michael Koldehoff; Yael Hegerfeldt; Rudolf Trenschel; Markus Ditschkowski; Sandra Christoph; Tanja Gromke; Lambros Kordelas; Hellmut D Ottinger; Rudolf S Ross; Peter A Horn; Susanne Schnittger; Dietrich W Beelen
Journal:  Blood       Date:  2011-05-03       Impact factor: 22.113

5.  Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors.

Authors:  C Söderberg-Nauclér; K N Fish; J A Nelson
Journal:  Cell       Date:  1997-10-03       Impact factor: 41.582

6.  Impact of cytomegalovirus replication and cytomegalovirus serostatus on the outcome of patients with B cell lymphoma after allogeneic stem cell transplantation.

Authors:  Jacopo Mariotti; Francesco Maura; Francesco Spina; Luisa Roncari; Anna Dodero; Lucia Farina; Vittorio Montefusco; Cristiana Carniti; Barbara Sarina; Francesca Patriarca; Alessandro Rambaldi; Francesco Onida; Attilio Olivieri; Francesco Zallio; Paolo Corradini
Journal:  Biol Blood Marrow Transplant       Date:  2014-02-28       Impact factor: 5.742

7.  High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma.

Authors:  Adrian J C Bloor; Kirsty Thomson; Noha Chowdhry; Stephanie Verfuerth; Stuart J Ings; Ronjon Chakraverty; David C Linch; Anthony H Goldstone; Karl S Peggs; Stephen Mackinnon
Journal:  Biol Blood Marrow Transplant       Date:  2008-01       Impact factor: 5.742

8.  Donor cytomegalovirus seropositivity and the risk of leukemic relapse after reduced-intensity transplants.

Authors:  David Nachbaur; Johannes Clausen; Brigitte Kircher
Journal:  Eur J Haematol       Date:  2006-02-15       Impact factor: 2.997

9.  Amplified NKG2C+ NK cells in cytomegalovirus (CMV) infection preferentially express killer cell Ig-like receptor 2DL: functional impact in controlling CMV-infected dendritic cells.

Authors:  Zakia Djaoud; Gaëlle David; Céline Bressollette; Catherine Willem; Pauline Rettman; Katia Gagne; Nolwenn Legrand; Souad Mehlal; Anne Cesbron; Berthe-Marie Imbert-Marcille; Christelle Retière
Journal:  J Immunol       Date:  2013-08-05       Impact factor: 5.422

10.  Cytomegalovirus-induced immunopathology and its clinical consequences.

Authors:  Stefania Varani; Maria Paola Landini
Journal:  Herpesviridae       Date:  2011-04-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.